Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors
Atezolizumab combined with vincristine, irinotecan, and temozolomide was feasible and well tolerated in children with solid tumors. Efficacy of this regimen is now being assessed in relapsed and refractory rhabdomyosarcoma in an ongoing Phase II cohort.
Authors
- Elizabeth Sokol (ORCID: https://orcid.org/0000-0002-1787-6901)
- Shoba A. Navai (ORCID: https://orcid.org/0000-0003-1220-2788)
- Brian Turpin (ORCID: https://orcid.org/0000-0002-3658-5659)
- Dinesh Rakheja (ORCID: https://orcid.org/0000-0001-6888-7902)
- Arhanti Sadanand (ORCID: https://orcid.org/0000-0002-7780-1688)
- Kenneth Chen (ORCID: https://orcid.org/0000-0003-2304-4631)
- Sharon Primeaux (ORCID: https://orcid.org/0009-0000-7358-8210)
- Natalie B. Collins (ORCID: https://orcid.org/0000-0003-2980-9244)
- Andrew Y. Koh (ORCID: https://orcid.org/0000-0003-2172-5126)
- David E. Gerber (ORCID: https://orcid.org/0000-0002-7812-6741)
- Avanthi Tayi Shah (ORCID: https://orcid.org/0000-0002-7125-3406)
- Katie M Albert
- Theodore Willis Laetsch (ORCID: https://orcid.org/0000-0002-8497-3138)
- Sonja E. Stutzman (ORCID: https://orcid.org/0000-0002-3121-2829)
- MinJae Lee (ORCID: https://orcid.org/0000-0002-4329-506X)
- Matthew Campbell
- Deseray Sida
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Children's Hospital of Philadelphia (US)
- Baylor College of Medicine (US)
- University of Washington (US)
- Lurie Children's Hospital (US)
- Texas Children's Hospital (US)
- Children's Cancer Center (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1002/pbc.32046
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Alex's Lemonade Stand Foundation for Childhood Cancer
- Genentech